Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.

Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH.

Int J Clin Exp Pathol. 2011 Jun 20;4(5):444-53. Epub 2011 Jun 11.

2.

The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.

Sato S, Trackman PC, Mäki JM, Myllyharju J, Kirsch KH, Sonenshein GE.

Mol Cell Biol. 2011 Jul;31(13):2683-95. doi: 10.1128/MCB.01148-10. Epub 2011 May 2.

3.

TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro.

Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, Thorburn A.

PLoS One. 2011 Jan 14;6(1):e14527. doi: 10.1371/journal.pone.0014527.

4.

Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer.

Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim SJ, Iwamoto T, Tamaki Y, Noguchi S.

Eur J Surg Oncol. 2011 Feb;37(2):155-61. doi: 10.1016/j.ejso.2010.10.009. Epub 2010 Dec 15.

PMID:
21111561
5.

Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis.

Min C, Zhao Y, Romagnoli M, Trackman PC, Sonenshein GE, Kirsch KH.

J Cell Biochem. 2010 Dec 1;111(5):1160-8. doi: 10.1002/jcb.22828.

6.

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.

Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J.

Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9.

PMID:
20617404
7.

Epithelial to mesenchymal transition in gingival overgrowth.

Sume SS, Kantarci A, Lee A, Hasturk H, Trackman PC.

Am J Pathol. 2010 Jul;177(1):208-18. doi: 10.2353/ajpath.2010.090952. Epub 2010 May 20.

8.

Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.

Petrović D, Babić D, Forko JI, Martinac I.

Coll Antropol. 2010 Mar;34(1):93-7.

PMID:
20437637
9.

Value of Ki67 in breast cancer: the debate is still open.

Colozza M, Sidoni A, Piccart-Gebhart M.

Lancet Oncol. 2010 May;11(5):414-5. doi: 10.1016/S1470-2045(10)70089-9. No abstract available.

PMID:
20434714
10.

Characterization of recombinant lysyl oxidase propeptide.

Vora SR, Guo Y, Stephens DN, Salih E, Vu ED, Kirsch KH, Sonenshein GE, Trackman PC.

Biochemistry. 2010 Apr 6;49(13):2962-72. doi: 10.1021/bi902218p.

11.

Ki67 in breast cancer: prognostic and predictive potential.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA.

Lancet Oncol. 2010 Feb;11(2):174-83. doi: 10.1016/S1470-2045(09)70262-1. Review.

PMID:
20152769
12.
13.

Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts.

Vora SR, Palamakumbura AH, Mitsi M, Guo Y, Pischon N, Nugent MA, Trackman PC.

J Biol Chem. 2010 Mar 5;285(10):7384-93. doi: 10.1074/jbc.M109.033597. Epub 2010 Jan 4.

14.

Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia.

Santisteban M, Reynolds C, Barr Fritcher EG, Frost MH, Vierkant RA, Anderson SS, Degnim AC, Visscher DW, Pankratz VS, Hartmann LC.

Breast Cancer Res Treat. 2010 Jun;121(2):431-7. doi: 10.1007/s10549-009-0534-7. Epub 2009 Sep 23.

15.

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.

Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N.

Breast Cancer. 2010 Oct;17(4):269-75. doi: 10.1007/s12282-009-0161-5.

PMID:
19730975
16.

A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.

Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE.

Cancer Res. 2009 Aug 15;69(16):6685-93. doi: 10.1158/0008-5472.CAN-08-4818. Epub 2009 Aug 4.

17.
18.

Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.

Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, Trackman PC.

Oncogene. 2009 Sep 24;28(38):3390-400. doi: 10.1038/onc.2009.203. Epub 2009 Jul 13.

19.

Treatment of cartilage defects in the knee using alginate beads containing human mature allogenic chondrocytes.

Almqvist KF, Dhollander AA, Verdonk PC, Forsyth R, Verdonk R, Verbruggen G.

Am J Sports Med. 2009 Oct;37(10):1920-9. doi: 10.1177/0363546509335463. Epub 2009 Jun 19.

PMID:
19542304
20.

The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells.

Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, Hallgrimsson B, Jirik FR.

PLoS One. 2009;4(5):e5620. doi: 10.1371/journal.pone.0005620. Epub 2009 May 19.

Supplemental Content

Support Center